Gilead Sciences Inc. released its pricing plan for Remdesivir, an antiviral drug that has proven highly effective in curing the coronavirus, according to a statement…
Gilead Sciences Inc. released its pricing plan for Remdesivir, an antiviral drug that has proven highly effective in curing the coronavirus, according to a statement issued Monday.
It will cost the U. S. government and other developed countries $2,340 for a standard 5-day treatment, while costing private insurers in the U. S. $3,120, per the statement.
Remdesivir has proven effective in treating COVID-19 cases four days faster compared to the placebo group, according to the Wall Street Journal.
